BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

The company forecast annual revenue of $4.28 billion to $4.4 billion for 2025, the midpoint of which is below analysts' ...

Carl Icahn’s Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund increased its stakes in two holdings, ...